Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis
H.-H. Chang, C.-H. Ho, B. Tomita, A. A. Silva, J. A. Sparks, E. W. Karlson, D. A. Rao, Y. C. Lee, I.-C. Ho
The paper identifies a PTPN22 gene signature in RA patients that can be reversed by targeted therapies and correlates with clinical response.
bioRxiv · Mar 24, 2019Immunology